Anticancer agent

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a pharmaceutical composition for the treatment and prevention of various cancers by delivering a peptide, protein, or gene sequence related to the Wech (also called TRIM71/Lin-41) protein family. The invention is built on the discovery that Wech acts as a tumor suppressor and that administration of Wech-related amino acid sequences or nucleic acid sequences can suppress tumor growth and prevent metastasis in a broad range of cancer types.

Use CasesContent extracted from patent full text and abstract with AI.

• Therapeutic treatment of solid and non-solid cancers such as thyroid, lung, liver, skin, ovary, pancreas, esophagus, and stomach cancers.
• Prevention and inhibition of tumor metastasis, especially in high-risk cancer patients.
• Prophylactic (preventive) use in individuals with genetic predispositions to certain cancers via gene therapy or peptide administration.
• Development of targeted anti-cancer drugs using specific Wech-related sequences to reduce adverse effects compared to conventional chemotherapy.
• Personalized cancer therapies based on specific variants or fragments of Wech proteins or genes, tailored to tumor type or patient.
• Potential use in combination with existing cancer treatments to enhance effectiveness and reduce resistance.
• Formulation of topical, injectable, or oral pharmaceuticals for both systemic and localized cancer treatment.

BenefitsContent extracted from patent full text and abstract with AI.

• Offers a novel therapeutic modality targeting the underlying genetics of cancer, potentially providing an alternative to traditional chemotherapy with fewer side effects.
• The Wech protein’s tumor-suppressor function may be effective across a wide spectrum of cancers, including difficult-to-treat and metastatic tumors.
• Use of peptides and gene sequences allows for specific and customizable targeting, enhancing therapeutic efficacy and minimizing collateral damage to healthy tissue.
• Potential for lower toxicity and better patient tolerance compared to cytotoxic chemotherapies and some antibody-based treatments.
• Pharmaceutical compositions can be formulated in various delivery modes (oral, injectable, topical, etc.), increasing flexibility for clinical use.
• Shorter protein or peptide fragments may further improve specificity and decrease side effects on other metabolic processes.
• Application of both human and non-human (e.g., mouse or fly) Wech sequences offers flexibility for drug design and optimization.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a pharmaceutical composition for the therapeutic and/or prophylactic treatment of cancer and/or metastasis thereof comprising an amino acid sequence related to a Wech protein and/or a nucleic acid sequence of the gene encoding for the Wech protein.